Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc. a healthcare company focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States Mexico Japan and China as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300 a GC-C agonist for the treatment of visceral pain conditions including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104 an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc. AstraZeneca AB and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia Inc. and changed its name to Ironwood Pharmaceuticals Inc. in April 2008. Ironwood Pharmaceuticals Inc. was incorporated in 1998 and is headquartered in Boston Massachusetts.